These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 21475175)

  • 1. Fix the antibiotics pipeline.
    Cooper MA; Shlaes D
    Nature; 2011 Apr; 472(7341):32. PubMed ID: 21475175
    [No Abstract]   [Full Text] [Related]  

  • 2. The drug push.
    Servick K
    Science; 2015 May; 348(6237):850-3. PubMed ID: 25999488
    [No Abstract]   [Full Text] [Related]  

  • 3. Examining Manufacturing Readiness for Breakthrough Drug Development.
    Dye E; Sturgess A; Maheshwari G; May K; Ruegger C; Ramesh U; Tan H; Cockerill K; Groskoph J; Lacana E; Lee S; Miksinski SP
    AAPS PharmSciTech; 2016 Jun; 17(3):529-38. PubMed ID: 26608693
    [No Abstract]   [Full Text] [Related]  

  • 4. What are the economic barriers of antibiotic R&D and how can we overcome them?
    Renwick M; Mossialos E
    Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug development: Time for teamwork.
    May M
    Nature; 2014 May; 509(7498):S4-5. PubMed ID: 24784427
    [No Abstract]   [Full Text] [Related]  

  • 6. Antibacterial R&D incentives.
    Laxminarayan R; Powers JH
    Nat Rev Drug Discov; 2011 Sep; 10(10):727-8. PubMed ID: 21959280
    [No Abstract]   [Full Text] [Related]  

  • 7. Eyes on new product development.
    Novack GD
    J Ocul Pharmacol Ther; 2013 Oct; 29(8):701. PubMed ID: 24073621
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibiotics: a shot in the arm.
    Leeb M
    Nature; 2004 Oct; 431(7011):892-3. PubMed ID: 15496888
    [No Abstract]   [Full Text] [Related]  

  • 9. A three-step plan for antibiotics.
    Nature; 2014 May; 509(7502):533. PubMed ID: 24877183
    [No Abstract]   [Full Text] [Related]  

  • 10. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.
    Spellberg B; Sharma P; Rex JH
    Nat Rev Drug Discov; 2012 Feb; 11(2):168. PubMed ID: 22293569
    [No Abstract]   [Full Text] [Related]  

  • 11. The GAIN Act legislation to combat antimicrobial resistance: Where do we stand?
    Sfeir MM
    Infect Control Hosp Epidemiol; 2018 Dec; 39(12):1499-1500. PubMed ID: 30334503
    [No Abstract]   [Full Text] [Related]  

  • 12. Re-engineering drug discovery and development.
    FitzGerald GA
    LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biotech entrepreneurs swoon over proposed fundraising changes.
    Venkataramanan M
    Nat Med; 2012 Jan; 18(1):3. PubMed ID: 22227645
    [No Abstract]   [Full Text] [Related]  

  • 14. Is the priority review voucher program stimulating new drug development for tropical diseases?
    Kerr KW; Henry TC; Miller KL
    PLoS Negl Trop Dis; 2018 Aug; 12(8):e0006695. PubMed ID: 30092022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
    Woosley RL; Myers RT; Goodsaid F
    Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In the midst of the antimicrobial discovery conundrum: an overview.
    Tomaras AP; Dunman PM
    Curr Opin Microbiol; 2015 Oct; 27():103-7. PubMed ID: 26356257
    [No Abstract]   [Full Text] [Related]  

  • 17. Report urges controversial 'delinkage' to foster new antibiotics.
    Holmes D
    Nat Med; 2014 Apr; 20(4):320. PubMed ID: 24710363
    [No Abstract]   [Full Text] [Related]  

  • 18. Q&A: Bernard Munos.
    Bender E
    Nature; 2016 May; 533(7602):S59. PubMed ID: 27167392
    [No Abstract]   [Full Text] [Related]  

  • 19. Medicine. Can intellectual property save drug development?
    FitzGerald GA
    Science; 2012 Oct; 338(6106):483-4. PubMed ID: 23112323
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel approaches are needed to develop tomorrow's antibacterial therapies.
    Spellberg B; Bartlett J; Wunderink R; Gilbert DN
    Am J Respir Crit Care Med; 2015 Jan; 191(2):135-40. PubMed ID: 25590154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.